Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of UGT Genetic Variation on Empagliflozin PK in Egyptians
NCT05036421Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Ain Shams University. Primary endpoints: Pharmacokinetic parameters at 48 hours and Bioavailability parameters at 24 hours. Started Feb 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05036421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036421.